» Articles » PMID: 16808151

Differential Effect of Lysophospholipids on Activities of Human Plasma Paraoxonase1, Either Soluble or Lipid-bound

Overview
Journal Lipids
Specialty Biochemistry
Date 2006 Jul 1
PMID 16808151
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Interaction of paraoxonase1 (PON1) with lysophospholipids was examined with respect to activity regulation and binding property. Paraoxonase activity of purified PON1 was partially inhibited by palmitoyl-lysophosphatidyl-glycerol (palmitoyl-lysoPG) and lysophosphatidylinositol (lysoPI), which had a stimulatory effect on arylesterase and diazoxonase activities. The selective inhibition of paraoxonase activity by palmitoyl-lysoPG, characterized by noncompetitiveness and charge interaction, was also observed with HDL- or dimyristoylphosphatidylcholine (DMPC)-bound PON1. Meanwhile, lysophosphatidylcholine (lysoPC) stimulated all three activities of purified PON1, although it stimulated DMPC-bound or HDL-bound PON1 to a lesser extent. The stimulatory action of lysophospholipids was observed around their CMC, suggesting that micelle formation of lysophospholpids might be involved in the stimulation of PON1 activity. Presumably in support of this, the tryptophan fluorescence intensity of PON1 was increased by lysophospholipids at concentrations required for the stimulation of PON1 activity. Separately, lysoPC stimulation was less remarkable for DMPC-bound PON1 than for either dimyristoylphosphatidylserine (DMPS)- or dimyristoylphosphatidylglycerol-bound PON1, suggesting a tight association between PON1 and DMPC. In support of this, the stimulatory role of apolipoprotein A-I was less prominent for DMPC-bound PON1 than for DMPS-bound PON1. Taken together, these data suggest that the inhibition of paraoxonase activity by lysoPG or lysoPI may be due to binding to a site distinct from the active center, whereas the stimulation by lysophospholipid may be ascribed to the micelle formation around the lipid-associable region of PON1.

Citing Articles

Endothelial Lipase Modulates Paraoxonase 1 Content and Arylesterase Activity of HDL.

Schilcher I, Stadler J, Lechleitner M, Hrzenjak A, Berghold A, Pregartner G Int J Mol Sci. 2021; 22(2).

PMID: 33450841 PMC: 7828365. DOI: 10.3390/ijms22020719.


The Early Effect of Carotid Artery Stenting on Antioxidant Capacity and Oxidative Stress in Patients with Carotid Artery Stenosis.

Michalak S, Ambrosius W, Wysocka E, Dziarmaga M, Juszkat R, Wykretowicz A Oxid Med Cell Longev. 2017; 2016:1789596.

PMID: 28058087 PMC: 5187477. DOI: 10.1155/2016/1789596.

References
1.
Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I . Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2002; 252(2):63-7. DOI: 10.1007/s004060200013. View

2.
Sorenson R, Bisgaier C, Aviram M, Hsu C, Billecke S, La Du B . Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999; 19(9):2214-25. DOI: 10.1161/01.atv.19.9.2214. View

3.
Bargota R, Akhtar M, Biggadike K, Gani D, Allemann R . Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg Med Chem Lett. 2003; 13(10):1623-6. DOI: 10.1016/s0960-894x(03)00290-7. View

4.
Getz G, Reardon C . Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol. 2004; 15(3):261-7. DOI: 10.1097/00041433-200406000-00005. View

5.
Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C . Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000; 28(11):1335-42. View